The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Immunotherapeutics against multiple myeloma: it’s all about BCMA
Enrique Ocio, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, gives an account of current immunotherapies for multiple myeloma (MM) at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France. Dr Ocio highllights how BCMA-targeting antibody-drug conjugates are among the most promising, as they can directly deliver treatment to the tumor cell. He also mentions the promise of BCMA-targeting CAR T-cells, as well as how BCMA/CD3 bispecific antibodies also appear to be effective.
